A European positioning strategy for MaaT Pharma's microbiome-based oncology leadership
MaaT Pharma is at a critical juncture. The EMA marketing authorisation process for your lead asset reaches a key milestone this September/October. Simultaneously, you face a broader strategic question: how should Europe understand and position MaaT Pharma for the next decade?
Navigate a significant regulatory milestone responsibly while building momentum around your oncology platform.
Move beyond being seen as a French biotech or single-asset company. Position MaaT Pharma as a European pioneer in microbiome-based cancer care.
This is the human story at the heart of MaaT Pharma. Behind the science, regulation, and innovation metrics lies a fundamental commitment to improving patient outcomes. This narrative—authentic, emotionally grounded, and clinically rigorous—is what will distinguish MaaT Pharma in Europe's healthcare landscape.
Simultaneously, Europe is positioned to lead the next generation of microbiome therapeutics. MaaT Pharma can credibly occupy a unique position: not just as a leading company in the field, but as one of the voices defining European scientific leadership.
MaaT Pharma should speak with one clear voice across media, stakeholder, and digital channels.
Communications must be ambitious yet responsible, accurate, and aligned with regulatory considerations.
The immediate milestone matters, but the goal is strengthening European profile for growth ahead.
Define clear positioning for MaaT Pharma as a European oncology platform company pioneering microbiome-based therapeutics. Move beyond perceptions as a French biotech or single-asset company.
Build visibility through selected, high-quality media relationships focused on three narratives: MaaT as European platform · microbiome as emerging approach · human story of patient impact. Connect to EU news cycle and policy moments (Biotech Act, etc).
Build recognition and favourability through multi-channel approach: thought leadership, digital communications, event visibility, stakeholder engagement, human storytelling. Make complex science accessible while reinforcing European identity.
Every transformative company has a founder's story. MaaT Pharma's CEO narrative connects personal commitment to patient impact—this is what resonates with clinicians, investors, and the broader healthcare community.
We will develop:
A phased engagement: a focused project around the EMA milestone in 2026, transitioning to an ongoing retainer to sustain positioning through 2027.
WR White Rabbit Brussels RP Rud Pedersen Brussels. All figures exclude VAT where applicable and any third-party costs incurred on your behalf.
This proposal is built on a collaboration between White Rabbit and Rud Pedersen Brussels. The partnership brings together complementary expertise around a shared objective: supporting MaaT Pharma with an integrated strategy that addresses communications, media, stakeholder engagement, and narrative building.
A senior, bespoke team combining creative, communications strategy, EU insight and media experience.
One integrated team. Clear roles. Consistent messaging. Shared success.
We're ready to move forward. Let's discuss the roadmap and timeline with your team.
Get in Touch